Citigroup
HQL

Citigroup’s abrdn Life Sciences Investors HQL Stock Holding History

Citigroup’s Portfolio HQL Stock Details HQL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-2,506
Closed -$54K – 6016
2021
Q2 		$54K Sell
2,506
-34,977
-93% -$706K ﹤0.01% 4783
2021
Q1 		$739K Buy
37,483
+5,337
+17% +$110K ﹤0.01% 3194
2020
Q4 		$635K Buy
32,146
+6,024
+23% +$111K ﹤0.01% 3989
2020
Q3 		$459K Buy
26,122
+2,747
+12% +$49.2K ﹤0.01% 3922
2020
Q2 		$420K Buy
23,375
+2,662
+13% +$45.6K ﹤0.01% 4428
2020
Q1 		$310K Buy
20,713
+6,805
+49% +$111K ﹤0.01% 4326
2019
Q4 		$242K Buy
13,908
+5,977
+75% +$98.1K ﹤0.01% 5024
2019
Q3 		$120K Buy
7,931
+5,787
+270% +$92.7K ﹤0.01% 5539
2019
Q2 		$36K Buy
2,144
+86
+4% +$1.42K ﹤0.01% 6738
2019
Q1 		$35K Hold
2,058
– – ﹤0.01% 6618
2018
Q4 		$31K Buy
2,058
+57
+3% +$1K ﹤0.01% 6602
2018
Q3 		$41K Buy
2,001
+39
+2% +$776 ﹤0.01% 6680
2018
Q2 		$37K Buy
1,962
+28
+1% +$527 ﹤0.01% 6510
2018
Q1 		$37K Buy
1,934
+40
+2% +$801 ﹤0.01% 6382
2017
Q4 		$37K Buy
1,894
+76
+4% +$1.52K ﹤0.01% 6374
2017
Q3 		$39K Sell
1,818
-2
-0.1% -$42 ﹤0.01% 6121
2017
Q2 		$38K Sell
1,820
-93,701
-98% -$1.89M ﹤0.01% 5961
2017
Q1 		$1.85M Sell
95,521
-23,794
-20% -$441K ﹤0.01% 2576
2016
Q4 		$2.03M Buy
119,315
+72,763
+156% +$1.28M ﹤0.01% 2926
2016
Q3 		$872K Buy
46,552
+40,807
+710% +$769K ﹤0.01% 3369
2016
Q2 		$98K Sell
5,745
-45,191
-89% -$834K ﹤0.01% 5092
2016
Q1 		$914K Buy
50,936
+44,995
+757% +$817K ﹤0.01% 3441
2015
Q4 		$140K Sell
5,941
-27,275
-82% -$677K ﹤0.01% 5066
2015
Q3 		$748K Buy
33,216
+27,501
+481% +$770K ﹤0.01% 3355
2015
Q2 		$161K Sell
5,715
-491
-8% -$13.6K ﹤0.01% 4607
2015
Q1 		$171K Buy
6,206
+687
+12% +$18.7K ﹤0.01% 4657
2014
Q4 		$137K Buy
5,519
+4,191
+316% +$101K ﹤0.01% 4985
2014
Q3 		$29K Buy
1,328
+525
+65% +$11.4K ﹤0.01% 5659
2014
Q2 		$17K Buy
803
+15
+2% +$315 ﹤0.01% 5883
2014
Q1 		$17K Buy
788
+103
+15% +$2.29K ﹤0.01% 6116
2013
Q4 		$14K Sell
685
-803
-54% -$15.6K ﹤0.01% 6308
2013
Q3 		$29K Buy
1,488
+826
+125% +$15.8K ﹤0.01% 5678
2013
Q2 		$12K Buy
+662
New +$12K ﹤0.01% 6026

Other funds holding HQL

NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return
AAM
Advisors Asset Management Monument, Colorado $6.01B AUM 24.74% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
FHA
Flagship Harbor Advisors Boston, Massachusetts $2.27B AUM 18.34% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Cohen & Steers
Cohen & Steers New York $57.6B AUM 8.03% 1-Year Est. Return
Cetera Investment Advisers
Cetera Investment Advisers Schaumburg, Illinois $94B AUM 20.14% 1-Year Est. Return

Citigroup's HQL Position: Q3 2021 in Review

Citigroup sold out of abrdn Life Sciences Investors (HQL) in Q3 2021, closing a stake of 2,506 shares — an estimated $54K sold.

Citigroup first reported a position in HQL in Q2 2013 and held it in 33 quarters. The position peaked at $2.03M in Q4 2016. 67 funds tracked by Wall St. Rank hold HQL as of Q3 2021.

  • Citigroup reported no remaining abrdn Life Sciences Investors position as of Q3 2021 after selling out during the quarter.
  • Citigroup sold 2,506 abrdn Life Sciences Investors shares in Q3 2021, an estimated $54K.
  • Citigroup first reported a position in abrdn Life Sciences Investors in Q2 2013 and held it in 33 quarters.
  • Citigroup's abrdn Life Sciences Investors position peaked at $2.03M in Q4 2016.
  • 67 funds tracked by Wall St. Rank held abrdn Life Sciences Investors as of Q3 2021.

Based on Citigroup's 13F filing for Q3 2021, filed 10 Nov 2021.